Celecoxib is a highly selective COX-2 inhibitor and primarily inhibits prostaglandin production. Celecoxib is approximately 7.6-fold more selective for COX-2 inhibition over COX-1. This specificity allows celecoxib to reduce inflammation and pain while minimizing gastrointestinal adverse drug reactions (e.g. stomach ulcers) that are common with non-selective non-steroidal anti-inflammatory drugs (NSAIDs).
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.